Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00170690
Status:
COMPLETED
Last Update Posted:
2013-06-03
First Post:
2005-09-12
Brief Title:
Preference Study With Elderly Patients Recurrent Ovarian Cancer
Sponsor:
North Eastern German Society of Gynaecological Oncology
Organization:
North Eastern German Society of Gynaecological Oncology
Study Overview
Official Title:
Präferenz-Studie Bei älteren Patientinnen Mit Ovarialkarzinomrezidiv Treosulfan Oral vs intravenös
Status:
COMPLETED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Comparison of the patient compliance treosulfan oral vs intravenous defined as end of therapy for the patient
Detailed Description:
Approximately 60 of all cancer diseases appear to people aged 65 years and older Ovarian cancer is the most frequent cause of death among gynaecological malignant tumours Since the highest carcinoma incidence is between the 60th and 70th year more women will come down with ovarian cancer because of increased life expectancy At least 65 of patients with FIGO stage IIIIV will exhibit a relapse or progress after first-line therapy In most studies the age of the patients is limited to 65 years It could be shown that especially elder patients often receive an inadequate operative and cytostatic therapy resulting in a worse prognosis
Patients aged 70 years or elder who will be treated with treosulfan given oral or intravenous shall be compared regarding the patient compliance toxicity especially hematological and gastrointestinal toxicity grade 3-4 CTC NCI overall survival progression free survival quality of life
Patients aged 70 years or elder who will be treated with treosulfan given oral or intravenous shall be compared regarding the patient compliance toxicity especially hematological and gastrointestinal toxicity grade 3-4 CTC NCI overall survival progression free survival quality of life
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None